BR0215896A - Tratamento enzimático da retinitis pigmentosa e composição farmacêutica relevante para o mesmo em forma de um kit - Google Patents

Tratamento enzimático da retinitis pigmentosa e composição farmacêutica relevante para o mesmo em forma de um kit

Info

Publication number
BR0215896A
BR0215896A BR0215896-5A BR0215896A BR0215896A BR 0215896 A BR0215896 A BR 0215896A BR 0215896 A BR0215896 A BR 0215896A BR 0215896 A BR0215896 A BR 0215896A
Authority
BR
Brazil
Prior art keywords
kit
pharmaceutical composition
retinitis pigmentosa
enzymatic treatment
relevant pharmaceutical
Prior art date
Application number
BR0215896-5A
Other languages
English (en)
Inventor
Paola Ammannati
Roberto Giordani
Original Assignee
Paola Ammannati
Roberto Giordani
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Paola Ammannati, Roberto Giordani filed Critical Paola Ammannati
Publication of BR0215896A publication Critical patent/BR0215896A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A61K38/443—Oxidoreductases (1) acting on CH-OH groups as donors, e.g. glucose oxidase, lactate dehydrogenase (1.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4813—Exopeptidases (3.4.11. to 3.4.19)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
    • C12Y101/01—Oxidoreductases acting on the CH-OH group of donors (1.1) with NAD+ or NADP+ as acceptor (1.1.1)
    • C12Y101/01021—Aldehyde reductase (1.1.1.21), i.e. aldose-reductase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
    • C12Y101/01—Oxidoreductases acting on the CH-OH group of donors (1.1) with NAD+ or NADP+ as acceptor (1.1.1)
    • C12Y101/01049—Glucose-6-phosphate dehydrogenase (1.1.1.49)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y111/00—Oxidoreductases acting on a peroxide as acceptor (1.11)
    • C12Y111/01—Peroxidases (1.11.1)
    • C12Y111/01009—Glutathione peroxidase (1.11.1.9)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/13—Dipeptidases (3.4.13)
    • C12Y304/13009—Xaa-Pro dipeptidase (3.4.13.9) i.e. prolidase

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

"TRATAMENTO ENZIMáTICO DA RETINITIS PIGMENTOSA E COMPOSIçãO FARMACêUTICA RELEVANTE PARA O MESMO EM FORMA DE UM KIT". A presente invenção refere-se a um kit para o tratamento da retinitis pigmentosa que contém as enzimas glutationa peroxidase, prolidase, glicose-6-fosfato desidrogenase e de modo opcional a aldose redutase em partes de alíquota e em quantidades interativas apropriadas para a administração das referidas enzimas de acordo com uma seq³ência de tempo pre-determinada.
BR0215896-5A 2002-10-01 2002-10-01 Tratamento enzimático da retinitis pigmentosa e composição farmacêutica relevante para o mesmo em forma de um kit BR0215896A (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IT2002/000624 WO2004030693A1 (en) 2002-10-01 2002-10-01 Enzymatic treatment of retinitis pigmentosa and relevant pharmaceutical composition in form of a kit

Publications (1)

Publication Number Publication Date
BR0215896A true BR0215896A (pt) 2005-08-09

Family

ID=32051201

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0215896-5A BR0215896A (pt) 2002-10-01 2002-10-01 Tratamento enzimático da retinitis pigmentosa e composição farmacêutica relevante para o mesmo em forma de um kit

Country Status (12)

Country Link
US (1) US7445777B2 (pt)
EP (1) EP1545590B1 (pt)
JP (1) JP2006504715A (pt)
CN (1) CN1321691C (pt)
AT (1) ATE330625T1 (pt)
AU (1) AU2002349813A1 (pt)
BR (1) BR0215896A (pt)
CA (1) CA2500068A1 (pt)
DE (1) DE60212729T2 (pt)
ES (1) ES2266601T3 (pt)
NZ (1) NZ538969A (pt)
WO (1) WO2004030693A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2567205A1 (en) * 2004-06-08 2005-12-22 Paola Ammannati Enzymatic treatment of retinitis pigmentosa and relevant pharmaceutical composition therefor in form of a kit
US20110021974A1 (en) * 2010-10-05 2011-01-27 Shantha Totada R Retinitis pigmentosa treatment and prophalaxis
CA2922570A1 (en) * 2013-08-26 2015-03-05 Health Research, Inc. Method for prophylaxis and/or treatment of erbb2 positive cancers
US10478477B2 (en) 2014-08-20 2019-11-19 Health Research, Inc. Method for prophylaxis or treatment of erbb1 positive cancers using a variant peptidase d with reduced activity

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2784030B1 (fr) 1998-10-02 2002-12-20 Inst Nat Sante Rech Med Utilisation de bloqueurs des canaux calciques et/ou cgmp-dependants pour le traitement de pathologies de la retine
FR2784898A1 (fr) 1998-10-26 2000-04-28 Univ Pasteur Utilisation du gdnf pour le traitement de la degenerescence retinienne

Also Published As

Publication number Publication date
DE60212729D1 (de) 2006-08-03
EP1545590B1 (en) 2006-06-21
ATE330625T1 (de) 2006-07-15
CA2500068A1 (en) 2004-04-15
NZ538969A (en) 2006-06-30
WO2004030693A1 (en) 2004-04-15
CN1321691C (zh) 2007-06-20
CN1671411A (zh) 2005-09-21
AU2002349813A1 (en) 2004-04-23
ES2266601T3 (es) 2007-03-01
US20060134088A1 (en) 2006-06-22
US7445777B2 (en) 2008-11-04
EP1545590A1 (en) 2005-06-29
DE60212729T2 (de) 2007-06-28
JP2006504715A (ja) 2006-02-09

Similar Documents

Publication Publication Date Title
WO2005016227A3 (en) Methods and pharmaceutical compositions for modulating heparanase activation and uses thereof
WO2007061939A3 (en) Metabolite derivatives of the hdac inhibitor fk228
AU2003287274A1 (en) Devices and methods for treating aortic valve stenosis
WO2005041924A3 (en) Administration of levodopa and carbidopa
IL183088A0 (en) Inhibitors of 11-?? hydroxyl steroid dehydrogenase type 1 and methods of using the same
WO2005082341A3 (en) NON-PEPTIDYL AGENTS WITH pHSP20-LIKE ACTIVITY, AND USES THEREOF
WO2003093441A3 (en) A method of regulating gene expression
WO2008053232A3 (en) Mycotoxin-reducing composition
AU2003216058A1 (en) Mammalian neural stem cells, compositions and uses thereof
WO2006045119A3 (en) Improved inhibitors for the soluble epoxide hydrolase
WO2006005581A3 (en) A composition comprising a pharmacologically active agent coupled to a target cell specific component, and a saponin
AU2003205315A1 (en) Methods and kits for delivering pharmaceutical agents into the coronary vascular adventitia
WO2008088884A3 (en) Enhanced cell-free synthesis of active proteins containing disulfide bonds
WO2005044199A3 (en) Combination of proton pump inhibitor and sleep aid
EP2264158A3 (en) Lipolytic enzyme variants
AU2003293555A1 (en) 17 beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
WO2004064736A3 (en) Treatment of benign prostatic hyperplasia using energolytic agents
WO2006013261A3 (fr) Utilisation de fibroblastes gingivaux en therapie cellulaire vasculaire.
WO2005094761A8 (en) Hair treatment compositions comprising a disaccharide, a di-acid and a source of ammonium ions
WO2005067673A3 (en) Enzymatic method to produce 7-dehydropregnenolone, vitamin d3-like compounds and derivatives thereof
BR0215896A (pt) Tratamento enzimático da retinitis pigmentosa e composição farmacêutica relevante para o mesmo em forma de um kit
AU2003235506A1 (en) Targeted enzymes and methods of making and using targeted enzymes.
ZA200502909B (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 and type 2.
EP1441708A4 (en) COMPOSITIONS AND METHODS FOR INCREASING THERAPEUTIC OBSERVANCE BY MEANS OF ALDEHYDE DEHYDROGENASE INHIBITORS AND TREATMENT OF ALCOHOLISM
PL1685248T3 (pl) Oksydoreduktaza z Metschnikowia Zobellii

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A , 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2069 DE 31/08/2010.